Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

27.54CHF
15 Jun 2018
Change (% chg)

CHF-0.24 (-0.86%)
Prev Close
CHF27.78
Open
CHF27.78
Day's High
CHF28.30
Day's Low
CHF27.38
Volume
389,803
Avg. Vol
318,696
52-wk High
CHF30.70
52-wk Low
CHF10.00

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF3,280.66
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): 62.47 240.92 34.18
EPS (TTM): 0.44 -- --
ROI: 2.21 -5.87 13.17
ROE: 4.05 -7.71 15.15

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 11 2018

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 16 2018

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

Apr 19 2018

BRIEF-Idorsia FY US GAAP Loss Of CHF 8 Million

* US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION

Feb 06 2018

Earnings vs. Estimates